Valuation: Exact Sciences Corporation

Market Cap 2TCr 1.75TCr 1.62TCr 1.51TCr 2.84TCr 1,89300Cr 2.89TCr 19TCr 7.54TCr 93TCr 7.52TCr 7.36TCr 3,25500Cr P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 2.16TCr 1.89TCr 1.74TCr 1.63TCr 3.07TCr 2,04200Cr 3.12TCr 21TCr 8.13TCr 1,00800Cr 8.11TCr 7.93TCr 3,51000Cr EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+2.92%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
125.6
10 years 11.48
Extreme 11.48
159.54
Date Insider Type Main position Quantity % Market Cap.
23/03Issuer sale

Director

26,038 0.0136%
23/03Issuer sale

Director

60,759 0.0318%
23/03Free

Executive/Senior Manager

1,99,374 0.1044%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+95.55%+11.27% 2TCr
-2.43%+10.42%+114.50%+127.11% 480.27Cr
+0.23%+23.49%+81.93%+214.52% 342.49Cr
-2.34%-4.16%-28.70%-41.77% 202.71Cr
-1.19%+2.46%+146.15%-40.99% 187.98Cr
-2.66%+13.77%+48.21%+232.94% 151.26Cr
-2.35%+18.86%+152.63%-50.12% 94Cr
-2.46%+9.59%-10.00%+44.17% 91Cr
+6.50%-1.73%+24.13% - 51Cr
-1.37%-6.17%-38.23%-20.03% 47Cr
Average -0.68%+8.92%+58.62%+53.01% 365.06Cr
Weighted average by Cap. -0.11%+5.55%+86.62%+48.47%

Financials

2024 2025
Net sales 275.89Cr 241.48Cr 222.92Cr 207.94Cr 391.79Cr 26TCr 398.79Cr 2.67TCr 1.04TCr 13TCr 1.04TCr 1.01TCr 45TCr 324.7Cr 284.21Cr 262.36Cr 244.73Cr 461.11Cr 31TCr 469.35Cr 3.15TCr 1.22TCr 15TCr 1.22TCr 1.19TCr 53TCr
Net income -102.89Cr -90Cr -83Cr -78Cr -146.11Cr -9.73TCr -148.72Cr -997.17Cr -387.13Cr -4.8TCr -386.54Cr -377.91Cr -17TCr -21Cr -18Cr -17Cr -16Cr -30Cr -1.97TCr -30Cr -201.54Cr -78Cr -970.24Cr -78Cr -76Cr -3.38TCr
Net Debt 173.77Cr 152.1Cr 140.41Cr 130.97Cr 246.77Cr 16TCr 251.19Cr 1.68TCr 653.85Cr 8.11TCr 652.86Cr 638.28Cr 28TCr 157.01Cr 137.43Cr 126.87Cr 118.34Cr 222.97Cr 15TCr 226.96Cr 1.52TCr 590.79Cr 7.33TCr 589.89Cr 576.72Cr 26TCr
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock